Working… Menu

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02732171
Recruitment Status : Recruiting
First Posted : April 8, 2016
Last Update Posted : September 17, 2020
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:

This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse.

Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Patients who harbor DTCs will be offered the opportunity for enrollment into a clinical trial of therapy targeting DTCs to prevent recurrence (separate protocols).

Condition or disease Intervention/treatment Phase
Breast Cancer Other: Plasma/Buffy Coat Other: Serum Other: Bone Marrow Aspirate Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Primary Purpose: Screening
Official Title: PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Study Start Date : April 2016
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Screening Bone Marrow Aspirate
All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs).
Other: Plasma/Buffy Coat
3 x 10ml EDTA Tube

Other: Serum
1 x 8.5ml Serum Separator Tube

Other: Bone Marrow Aspirate
1 x 10ml EDTA Tube

Primary Outcome Measures :
  1. Number of disseminated tumor cells [ Time Frame: 3 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-confirmed primary invasive breast cancer within 5 years of study entry
  • Pathologically-confirmed invasive breast cancer in axillary lymph nodes or tumor with triple negative subtype: negative estrogen receptor (ER), progesterone receptor (PR) and Her2-overexpression by ASCO-CAP guidelines or tumor with a Breast Cancer Recurrence Score of ≥ 25 per the Genomic Health Oncotype DX breast cancer test, or residual disease after neoadjuvant chemotherapy.
  • Completed all primary therapy (surgery, (neo)adjuvant chemotherapy and adjuvant radiation) for the index malignancy with
  • No evidence of local or distant recurrent disease by physical examination, blood tests (CBC, LFTs, Alk Phos), or symptom-directed imaging, per NCCN guidelines.
  • Normal coagulation studies: PT and PTT ≤ 1.5 x upper limit of normal per institutional laboratory range and for patients on warfarin, INR < 3.0. For patients on therapeutic anti-coagulants, medication must be clinically held peri-procedure per standard clinical management.
  • Willing to undergo bone marrow aspiration and blood specimen collection per protocol specifications
  • Age 18 or over and able to give informed consent
  • Patient has no evidence of meeting exclusion criteria for companion clinical trials.

Exclusion Criteria:

  • Concurrent enrollment on another investigational therapy
  • Patients receiving chronic, high dose systemic treatment with corticosteroids defined as: chronic use of cortisone >50mg; hydrocortisone >40mg, prednisone >10mg, methylprednisone >8mg or dexamethasone >1.5mg; or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

Symptomatic congestive heart failure of New York heart Association Class III or IV Unstable angina pectoris, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease Severely impaired lung function with a previously documented spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air Uncontrolled diabetes Active (acute or chronic) or uncontrolled severe infections Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis A known history of HIV seropositivity as reported by the patient Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) Patients with an active, bleeding diathesis

  • Female patients who are pregnant or breast feeding. Women of childbearing potential must have a negative urine or serum pregnancy test.
  • Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).
  • Patients with a known hypersensitivity to Everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
  • A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02732171

Layout table for location contacts
Contact: Angela DeMichele, MD 855-216-0098

Layout table for location information
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Angela DeMichele, MD    855-216-0098   
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Layout table for investigator information
Principal Investigator: Angela DeMichele, MD Abramson Cancer Center of the University of Pennsylvania
Layout table for additonal information
Responsible Party: Abramson Cancer Center of the University of Pennsylvania Identifier: NCT02732171    
Other Study ID Numbers: UPCC 28115
First Posted: April 8, 2016    Key Record Dates
Last Update Posted: September 17, 2020
Last Verified: September 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Disease Attributes
Pathologic Processes